I am interested in
  • Check All
  • Uncheck All
  • all subtypes
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Rare Lymphoma
  • T-Cell Lymphoma
  • / 1 checked
  • Only show this subtype

Interested in a specific sub-type?

Filter what you see here

  • Medical Information
  • Therapies
  • About

FL

ASH 2016: Why didn't the PFS improvement translate into an OS improvement?

Cynthia Umukoro | Dec 9, 2016 | Expert Opinion

Share this article

Related Medical Information

CLL/SLL|DLBCL|FL

Rituximab biosimilar, rixathon, given ‘positive opinion’ by the EMA CHMP for use in Follicular and Diffuse Large B-Cell…

May 4, 2017
DLBCL|FL

Mocetinostat has limited single-agent activity and acceptable toxicity profile in patients with relapsed/refractory…

May 10, 2017
DLBCL|FL|HL|TCL

ASH 2016 Oral Abstract #183 – phase I CheckMate 039: nivolumab plus ipilimumab for R/R HL, NHL and MM

Dec 6, 2016

Related Licenses

Rituxan (rituximab) is indicated for the treatment of patients with non-progressing (including stable…

Subtype: FL

INN: rituximab

Approval status: FDA

Setting: R/R

Zydelig is a kinase inhibitor indicated for the treatment of patients with relapsed Follicular B-cell…

Subtype: FL

INN: idelalisib

Approval status: FDA

Setting: R/R

Truxima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma…

Subtype: FL

INN: rituximab

Approval status: EMA

Setting: Newly Diagnosed

Our partners

Our supporters

  • Terms and conditions
  • Cookie policy
  • Newsletter

© 2017 Lymphoma Hub

All content on this site is intended for healthcare professionals only.
If you are a patient or carer, please visit the Lymphoma Coalition.